Premium
Shared decision making for hydroxyurea treatment initiation in children with sickle cell anemia
Author(s) -
Crosby Lori E.,
Shook Lisa M.,
Ware Russell E.,
Brinkman William B.
Publication year - 2015
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.25124
Subject(s) - medicine , sickle cell anemia , anemia , pediatrics , intensive care medicine , disease
Clinical trials have demonstrated hydroxyurea's efficacy in improving health outcomes for children with sickle cell anemia (SCA) who have medical complications. New NHLBI clinical guidelines will recommend offering hydroxyurea to young patients regardless of clinical severity. Shared decision making may be an effective approach for implementing this practice change. Decision aids that help patients/parents feel empowered to make this decision and help providers feel comfortable in discussing hydroxyurea as a preventive treatment may facilitate shared discussions between families and providers. We recommend six strategies providers can use to facilitate these discussions while decision aids and tools are being developed. Pediatr Blood Cancer 2015;62:184–185. © 2014 Wiley Periodicals, Inc.